Economic evaluation of PCV21 in PCV-naïve adults aged 50–64 years in the United States
An age-based vaccination strategy for adults aged 50-64 years in the US can lead to reductions in pneumococcal disease cases and associated mortality compared to a risk-based strategy. Moreover, PCV21 was a more effective and economically favorable option than PCV20 across a wide range of scenarios and input values.
Authors
- Elamin H. Elbasha (ORCID: https://orcid.org/0000-0002-9993-8036)
- Kwame Owusu‐Edusei (ORCID: https://orcid.org/0000-0002-4519-2857)
- Zinan Yi (ORCID: https://orcid.org/0009-0002-4997-3121)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Publication Details
- Journal
- Vaccine
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1016/j.vaccine.2025.127264
- Citations
- 2
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 2.71